This is very interesting company / story that has been highlighted on this forum.
On the business strategy of the Parent, their Vision seems to indicate that they want to grow Op Income from 2bn Yen / ~$15mm in 2024 to 4bn Yen / ~$30mm by 2031, or a 10% CAGR.
Given the expected tailwinds from value added products, shift from gelatin to collagen peptide - doesn’t this seem a bit low?
I’m just trying to understand if we can expect higher growth at the India entity, esp with the expected 3x in Collagen Peptide capacity
Thanks!
Subscribe To Our Free Newsletter |